Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,288.59 +11.08 (+0.21%) Dow
38,593.21 -93.11 (-0.24%) Nasdaq
16,844.62 +109.60 (+0.65%) Bitcoin USD
69,809.41 +1,698.02 (+2.49%) CMC Crypto 200
1,505.70 +37.77 (+2.57%)
SMMT Jun 2024 7.000 call
| Previous close | 2.6500 |
| Open | 3.2500 |
| Bid | 2.9500 |
| Ask | 3.6000 |
| Strike | 7.00 |
| Expiry date | 2024-06-21 |
| Day's range | 3.2500 - 3.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 341 |
Business WireSummit Raises $200 Million; Also Expands License Territories for Ivonescimab
MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million.
Business WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate
Business WireIvonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso.
